Elutia Inc. (NASDAQ:ELUT – Get Free Report) was the target of a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 33,661 shares, an increase of 119.6% from the October 15th total of 15,326 shares. Based on an average daily volume of 70,790 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.1% of the company’s stock are short sold.
Elutia Stock Up 3.5%
ELUT traded up $0.03 during mid-day trading on Monday, reaching $0.85. 39,828 shares of the stock were exchanged, compared to its average volume of 161,569. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.61 and a current ratio of 2.63. The stock has a market capitalization of $37.60 million, a PE ratio of 0.76 and a beta of 0.93. The company has a 50 day moving average price of $0.82 and a two-hundred day moving average price of $0.97. Elutia has a 1 year low of $0.50 and a 1 year high of $1.39.
Elutia (NASDAQ:ELUT – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.11. Elutia had a net margin of 546.70% and a negative return on equity of 140.53%. The company had revenue of $1.14 million during the quarter, compared to the consensus estimate of $1.00 million.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings cut shares of Elutia from a “sell (d)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Elutia presently has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on Elutia
Elutia Company Profile
Elutia is a medical technology company focused on developing biologic products for use in surgery. Its portfolio includes envelopes designed to support cardiac implantable electronic devices, such as pacemakers and defibrillators. The company’s products include CanGaroo, an extracellular-matrix envelope designed to help secure and support implanted devices, and EluPro, an antibiotic-eluting envelope intended to help reduce the risk of infection associated with these devices. Elutia was formerly known as Aziyo Biologics and adopted its current name in 2023 as it focused its business on drug-eluting biologic technologies.
Further Reading
- Five stocks we like better than Elutia
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
